A detailed history of New York State Common Retirement Fund transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 9,100 shares of CCCC stock, worth $39,858. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,100
Previous 23,700 61.6%
Holding current value
$39,858
Previous $109,000 52.29%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$4.43 - $7.38 $64,677 - $107,748
-14,600 Reduced 61.6%
9,100 $52,000
Q2 2024

Jul 31, 2024

BUY
$4.05 - $8.1 $95,985 - $191,970
23,700 New
23,700 $109,000
Q2 2023

Aug 07, 2023

SELL
$2.75 - $3.77 $20,746 - $28,440
-7,544 Reduced 95.93%
320 $1,000
Q1 2023

May 02, 2023

SELL
$3.1 - $9.02 $64,287 - $187,056
-20,738 Reduced 72.51%
7,864 $25,000
Q4 2022

Jan 30, 2023

BUY
$5.42 - $10.24 $135 - $256
25 Added 0.09%
28,602 $169,000
Q3 2022

Nov 08, 2022

BUY
$8.03 - $12.77 $1,003 - $1,596
125 Added 0.44%
28,577 $251,000
Q2 2022

Aug 04, 2022

SELL
$5.06 - $26.46 $450 - $2,354
-89 Reduced 0.31%
28,452 $215,000
Q1 2022

May 05, 2022

BUY
$19.99 - $33.23 $359 - $598
18 Added 0.06%
28,541 $692,000
Q4 2021

Feb 02, 2022

BUY
$29.39 - $46.86 $104,863 - $167,196
3,568 Added 14.3%
28,523 $918,000
Q3 2021

Nov 02, 2021

SELL
$35.91 - $50.5 $166,119 - $233,613
-4,626 Reduced 15.64%
24,955 $1.12 Million
Q2 2021

Aug 02, 2021

BUY
$30.39 - $42.18 $613,300 - $851,234
20,181 Added 214.69%
29,581 $1.12 Million
Q1 2021

May 11, 2021

BUY
$31.96 - $46.5 $51,136 - $74,400
1,600 Added 20.51%
9,400 $348,000
Q4 2020

Feb 08, 2021

BUY
$22.8 - $37.05 $177,840 - $288,990
7,800 New
7,800 $258,000

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $214M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.